Is HCV infection associated with liver steatosis also in children?

Journal of Hepatology

Volumn 45, Issue 3, 2006, Pages 350-354

  Giannattasio, Antonietta ^a   Spagnuolo, Maria Immacolata ^a   Sepe, Angela ^a   Valerio, Giuliana ^b   Vecchione, Raffaella ^a   Vegnente, Angela ^a   Iorio, Raffaele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

Author keywords

Children; Chronic hepatitis C; Liver fibrosis; Liver steatosis

Indexed keywords

INTERFERON;

ARTICLE; BODY MASS; CHILD; CLINICAL LABORATORY; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER METABOLISM; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM;

ADOLESCENT; BIOPSY; CHILD; CHILD, PRESCHOOL; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33746565999     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2006.03.010     Document Type: Article

References (23)

1. Hwang S.J., Luo J.C., Chu C.W., Lai C.R., Lu C.L., Tsay S.H., et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 16 (2001) 190-195
2. Hourigan L.F., Macdonald G.A., Purdie D., Whitehall V.H., Shorthouse C., Clouston A., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29 (1999) 1215-1219
3. Adinolfi L.E., Gambardella M., Andreana A., Tripodi M.F., Utili R., and Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
4. Kumar D., Farrell G.C., Fung C., and George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 36 (2002) 1266-1272
5. Hezode C., Roudot-Thoraval F., Zafrani E.S., Dhumeaux D., and Pawlotsky J.M. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 11 (2004) 455-458
6. Rubbia-Brandt L., Quadri R., Abid K., Giostra E., Male P.J., Mentha G., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33 (2000) 106-115
7. Castera L., Chouteau P., Hezode C., Zafrani E.S., Dhumeaux D., and Pawlotsky J.M. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 100 (2005) 711-715
8. Poynard T., Ratziu V., McHutchison J., Manns M., Goodman Z., Zeuzem S., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
9. Patton H.M., Patel K., Behling C., Bylund D., Blatt L.M., Vallee M., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40 (2004) 484-490
10. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. Gastroenterology 125 (2003) 1695-1704
11. Ratziu V., Munteanu M., Charlotte F., Bonyhay L., Poynard T., and LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39 (2003) 1049-1055
12. Castera L., Hezode C., Roudot-Thoraval F., Bastie A., Zafrani E.S., Pawlotsky J.M., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003) 288-292
13. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, et al. CDC growth charts: United States. Adv Data 2000;314:1-27 (http://www.cdc.gov/nccdphp/dnpa/growthcharts/sas.htm/).
14. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
15. Ishak K., Baptista A., Bianchi L., Callea F., De Groote J., Gudat F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
16. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
17. Mihm S., Fayyazi A., Hartmann H., and Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25 (1997) 735-759
18. Westin J., Nordlinder H., Lagging M., Norkrans G., and Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37 (2002) 837-842
19. Rubbia-Brandt L., Fabris P., Paganin S., Leandro G., Male P.J., Giostra E., et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53 (2004) 406-412
20. Muzzi A., Leandro G., Rubbia-Brandt L., James R., Keiser O., Malinverni R., et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients. J Hepatol 42 (2005) 41-46
21. Barba G., Harper F., Harada T., Kohara M., Goulinet S., Matsuura Y., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 94 (1997) 1200-1205
22. Lerat H., Honda M., Beard M.R., Loesch K., Sun J., Yang Y., et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122 (2002) 352-365
23. Akuta N., Suzuki F., Tsubota A., Suzuki Y., Someya T., Kobayashi M., et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 37 (2002) 831-836